Perrigo Company plc Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Perrigo Company plc (PRGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 0 shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2018-03-01
- Perrigo Company plc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2017 was 0.00 shares.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2016 was 0.00 shares.
- Perrigo Company plc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2015 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|
| 2017-12-31 | 0.00 shares 10-K · filed 2018-03-01 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-03-01 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2018-03-01 | |
| 2015-06-27 | 0.00 shares 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |